Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ALK7結合タンパク質およびその使用
Document Type and Number:
Japanese Patent JP7433222
Kind Code:
B2
Abstract:
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Inventors:
Rabindra, Kumar
Castong Eye, Roselin
Saco, Diane
Berg, Jonathan
Sharkey, Nathan Jay.
Application Number:
JP2020523427A
Publication Date:
February 19, 2024
Filing Date:
October 25, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Axelaron Pharma Incorporated
Adimab, LLC
International Classes:
C07K16/40; A61K39/395; A61P1/16; A61P3/00; A61P3/04; A61P3/06; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12N15/63; C12P21/08
Domestic Patent References:
JP10510143A
Foreign References:
WO2017177013A1
Other References:
Zhao F. et al.,Nodal induces apoptosis through activation of the ALK7 signaling pathway in pancreatic INS-1 β-cells,Am J Physiol Endocrinol Metab,2012年,Vol. 303,pp. E132-E143
Schlothauer T. et al.,Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,Protein Engineering, Design & Selection,2016年,Vol. 29,pp. 457-466
Kogame M. et al.,ALK7 is a novel marker for adipocyte differentiation,The Journal of Medical Investigation,2006年,Vol. 53,pp. 238-245
Attorney, Agent or Firm:
Patent Attorney Corporation Hiraki International Patent Office